Literature DB >> 26334687

The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Fernando Caravaggio1, Shinichiro Nakajima2, Eric Plitman1, Philip Gerretsen3, Jun Ku Chung1, Yusuke Iwata1, Ariel Graff-Guerrero4.   

Abstract

Understanding the interplay between the neurotransmitters dopamine and glutamate in the striatum has become the highlight of several theories of neuropsychiatric illnesses, such as schizophrenia. Using in vivo brain imaging in humans, alterations in dopamine and glutamate concentrations have been observed in several neuropsychiatric disorders. However, it is unclear a priori how alterations in striatal dopamine should modulate glutamate concentrations in the basal ganglia. In this selective mini-review, we examine the consequence of reducing striatal dopamine functioning on glutamate concentrations in the striatum and cortex; regions of interest heavily examined in the human brain imaging studies. We examine the predictions of the classical model of the basal ganglia, and contrast it with findings in humans and animals. The review concludes that chronic dopamine depletion (>4months) produces decreases in striatal glutamate levels which are consistent with the classical model of the basal ganglia. However, acute alterations in striatal dopamine functioning, specifically at the D2 receptors, may produce opposite affects. This has important implications for models of the basal ganglia and theorizing about neurochemical alterations in neuropsychiatric diseases. Moreover, these findings may help guide a priori hypotheses for (1)H-MRS studies measuring glutamate changes given alterations in dopaminergic functioning in humans.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26334687      PMCID: PMC5323253          DOI: 10.1016/j.pnpbp.2015.08.013

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  59 in total

Review 1.  The roles of co-transmission in neural network modulation.

Authors:  M P Nusbaum; D M Blitz; A M Swensen; D Wood; E Marder
Journal:  Trends Neurosci       Date:  2001-03       Impact factor: 13.837

2.  Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.

Authors:  Chi-Bong Choi; Sang-Young Kim; Sung-Ho Lee; Geon-Ho Jahng; Hwi-Yool Kim; Bo-Young Choe; Kyung-Nam Ryu; Dal-Mo Yang; Sung-Vin Yim; Woo-Suk Choi
Journal:  Magn Reson Imaging       Date:  2010-10-27       Impact factor: 2.546

Review 3.  The functional anatomy of disorders of the basal ganglia.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1995-02       Impact factor: 13.837

Review 4.  From glutamate co-release to vesicular synergy: vesicular glutamate transporters.

Authors:  Salah El Mestikawy; Asa Wallén-Mackenzie; Guillaume M Fortin; Laurent Descarries; Louis-Eric Trudeau
Journal:  Nat Rev Neurosci       Date:  2011-04       Impact factor: 34.870

5.  Glutamate is a cotransmitter in ventral midbrain dopamine neurons.

Authors:  S Rayport
Journal:  Parkinsonism Relat Disord       Date:  2001-07       Impact factor: 4.891

6.  Lower glutamate levels in rostral anterior cingulate of chronic cocaine users - A (1)H-MRS study using TE-averaged PRESS at 3 T with an optimized quantification strategy.

Authors:  Shaolin Yang; Betty Jo Salmeron; Thomas J Ross; Zheng-Xiong Xi; Elliot A Stein; Yihong Yang
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

7.  Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Camilo de la Fuente-Sandoval; Pablo León-Ortiz; Mariana Azcárraga; Sylvana Stephano; Rafael Favila; Leonardo Díaz-Galvis; Patricia Alvarado-Alanis; Jesús Ramírez-Bermúdez; Ariel Graff-Guerrero
Journal:  JAMA Psychiatry       Date:  2013-10       Impact factor: 21.596

8.  Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.

Authors:  S Robelet; C Melon; B Guillet; P Salin; L Kerkerian-Le Goff
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

Review 9.  Glutamate in dopamine neurons: synaptic versus diffuse transmission.

Authors:  Laurent Descarries; Noémie Bérubé-Carrière; Mustapha Riad; Grégory Dal Bo; J Alfredo Mendez; Louis-Eric Trudeau
Journal:  Brain Res Rev       Date:  2007-10-26

10.  Prefrontal and Striatal Glutamate Differently Relate to Striatal Dopamine: Potential Regulatory Mechanisms of Striatal Presynaptic Dopamine Function?

Authors:  Tobias Gleich; Lorenz Deserno; Robert Christian Lorenz; Rebecca Boehme; Anne Pankow; Ralph Buchert; Simone Kühn; Andreas Heinz; Florian Schlagenhauf; Jürgen Gallinat
Journal:  J Neurosci       Date:  2015-07-01       Impact factor: 6.167

View more
  3 in total

1.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

2.  Reduced Glutamate Turnover in the Putamen Is Linked With Automatic Habits in Human Cocaine Addiction.

Authors:  Karen D Ersche; Tsen Vei Lim; Alexander G Murley; Catarina Rua; Matilde M Vaghi; Tara L White; Guy B Williams; Trevor W Robbins
Journal:  Biol Psychiatry       Date:  2020-12-19       Impact factor: 13.382

3.  Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Authors:  Shamsher Singh; Sumit Jamwal; Puneet Kumar
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.